Multiplikator forward rega marang pendapatan: Ocugen, Inc. (OCGN)

Logo grafis Ocugen Corp (OCGN)

Developing unique treatments for ocular diseases and viruses requires extensive clinical testing, creating a temporary monopoly for Ocugen, Inc. (OCGN). The expected P/S ratio illustrates the business valuation trend, with the metric currently at 58.90. The company currently relies on grants after shifting its focus toward gene therapy, while strictly adhering to bioethics and environmental standards for chemical disposal in its laboratories.

OCGN ocugen.com: Rasio kapitalisasi pasar marang pendapatan mangsa ngarep ing interval 18.04.2024 - 15.11.2026

Rincian analitis lan laporan data perusahaan ocugen.com (OCGN)

- rega saiki lan proyeksi nilai saham:
- indikator kapitalisasi bursa perusahaan:
Pambiji fundamental perusahaan:Ocugen, Inc. OCGN
Sampel barang Ocugen, Inc.

Forward P/S compares current market capitalization with expected annual sales, demonstrating the premium investors are willing to pay for future revenue growth. When analyzing this forward price-to-sales valuation, it should be noted that for Ocugen, Inc. (OCGN), the multiple's dynamics depend directly on the pace of patient base expansion and strict compliance with FDA gene therapy safety regulations.

Analisis pesaing Ocugen, Inc.

Multiplikator Forward P/S TEM (Tempus Labs)|Qiagen N.V. - Rasio rega marang prakiraan pendapatan|IONS - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep repligen.com|RNA: Multiplikator Forward P/S|CRISPR Therapeutics Inc (CRSP) - Multiplikator Forward P/S|WGS (GeneDx Holdings) - Multiplikator Forward P/S|RARE: Rega forward marang dodolan|Multiplikator forward rega marang pendapatan BEAM (Beam Therapeutics Corp)|SRPT: Rega mangsa ngarep marang pendapatan|Multiplikator Forward P/S TWST (Twist Bioscience Inc)|Rasio kapitalisasi marang dodolan sing dikarepake 10x Genomics Corp (TXG)|intelliatx.com - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake Stoke STOK|biolifesolutions.com (BLFS) - Rasio rega marang prakiraan pendapatan|WVE - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator forward rega marang pendapatan MAZE|Multiplikator forward rega marang pendapatan Sionna Therapeutics, Inc. (SION)|Multiplikator forward rega marang pendapatan PRME (Prime Medicine Bio)|Rasio kapitalisasi marang dodolan sing dikarepake Taysha|uniQure Pharma - Multiplikator forward rega marang pendapatan|MeiraGTx Holdings plc - Rasio rega marang prakiraan pendapatan|regenxbio.com - Multiplikator Forward P/S|Solid Bio (SLDB) - Multiplikator forward rega marang pendapatan|PACB: Multiplikator Forward P/S|BNTC - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan Design Therapeutics, Inc.|RCKT: Rega forward marang dodolan|Multiplikator forward rega marang pendapatan FDMT (4D Molecular Therapeutics, Inc.)|Lexeo Therapeutics, Inc. - Kapitalisasi marang prakiraan pendapatan|Rasio rega marang prakiraan pendapatan Korro Bio, Inc. KRRO|EDIT: Kapitalisasi marang prakiraan pendapatan|SLN - Rasio rega marang prakiraan pendapatan|Prakiraan rega marang pendapatan ProQR Therapeutics (PRQR)|CDXS (Codexis Bio) - Multiplikator forward rega marang pendapatan|Sangamo Therapeutics Inc. (SGMO) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan Nautilus Bio|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Metagenomi Therapeutics MGX|Rasio rega marang prakiraan pendapatan Precision BioSciences (DTIL)|GBIO - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Multiplikator Forward P/S BOLD (Boundless Bio, Inc)|XCUR - Multiplikator forward rega marang pendapatan|IMNN - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Phio Pharmaceuticals Corp|MBIO: Multiplikator Forward P/S|TransCode (RNAZ) - Multiplikator Forward P/S|BNGO (Bionano) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Applied DNA Sciences, Inc. APDN|Multiplikator Forward P/S BLUE|ImmunoPrecise Antibodies Ltd - Kapitalisasi marang prakiraan pendapatan|Rasio rega marang prakiraan pendapatan Omega Therapeutics OMGA|OMIC: Kapitalisasi marang prakiraan pendapatan|RGLS: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan SYRS (Syros Pharmaceuticals, Inc.)|Telesis Bio, Inc. (TBIO) - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan TCON (TRACON)|Rasio rega marang prakiraan pendapatan Unity Biotechnology, Inc.